pharma · Primary Biliary Cirrhosis · Gastric Intestinal Metaplasia
Xijing Hospital of Digestive Diseases
Xijing Hospital of drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Xijing Hospital of drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor alpha.
Development asset linked to Xijing Hospital of in public FDA and regional records. Mechanism: Mitochondrial complex I (NADH dehydrogenase) inhibitor.